New at CADTH — August 2022

Corporate News and Events

Canada's Drug Agency Symposium: Springing Back to Spring in 2023

Canada's Drug Agency is preparing to bring back the usual time frame of the Canada's Drug Agency Symposium to the spring. Unfortunately, this means there will not be a 2022 Canada's Drug Agency Symposium. Instead, we are springing back to spring in 2023 with a hybrid Symposium that will provide both in-person and virtual attendance options. Stay tuned for a save the date.

Network Collaborators Announced for the Canada's Drug Agency Post-Market Drug Evaluation Network

Canada's Drug Agency is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation (PMDE) Network. Collaborators will bring additional expertise to the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.

The PMDE Program will launch September 1, 2022, and contracts will be issued to these individuals or teams as queries are received by the PMDE Program. Learn more.

Canada's Drug Agency Reports and Recommendations

Reimbursement Reviews

Drug funding recommendations for Canada's federal, provincial, and territorial public drug programs. Reimbursement recommendations are based on comprehensive assessments of the clinical and pharmacoeconomic evidence, as well as input from pharmaceutical companies, clinicians, and patient groups.

• elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta) for cystic fibrosis, F508del CFTR mutation
• tafamidis (Vyndaqel) for Transthyretin-mediated amyloidosis
• amifampridine phosphate (Firdapse) for Lambert-Eaton Myasthenic Syndrome
• cenegermin (Oxervate) for neurotrophic keratitis
• avalglucosidase alfa (Nexviazyme) for Pompe disease
• immune globulin human and recombinant human hyaluronidase (HyQvia) for humoral immunodeficiency
• lenvatinib and pembrolizumab (Lenvima and Keytruda) for advanced or metastatic renal cell carcinoma
• selpercatinib (Retevmo) for thyroid cancer
• lisocabtagene maraleucel (Breyanzi) for relapsed or refractory large B-cell lymphoma

Canada's Drug Agency Horizon Scans

Information about new and emerging health technologies that could impact the delivery of care in Canada.

• Trace Amine-Associated Receptor 1 Agonists for Schizophrenia - Emerging Health Technologies
• Autologous Hematopoietic Stem Cell Transplant for People With Multiple Sclerosis - Optimal Use

Canada's Drug Agency Health Technology Reviews

Independent assessments of health technologies. Assessments consist of 1, or a combination, of the following: an Environmental Scan, a Rapid Review, a Clinical or Systematic) Review, an Economic Review, and a review of patient perspectives. They may also include an assessment of the legal, ethical, social, implementation, environmental, and policy implications of the health technology. Recommendations on the appropriate use of health technologies are provided if applicable.

• Diacetylmorphine for Adults With Opioid Dependence – Rapid Review
• Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder – Rapid Review
• Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma – Rapid Review
• Models of Care for People Re-Entering the Community After Incarceration – Technology Review
• Vandetanib for Medullary Thyroid Cancer – Technology Review
• Improving Access to Primary Care in Canada – Environmental Scan
• Predictive Maintenance for Medical Imaging Equipment – CMII Report

Canada's Drug Agency Reference Lists

Lists of the publicly available and grey literature that identify the evidence and the gaps in the scientific literature.

• Screening for Asymptomatic Bacteriuria During Pregnancy
• Liposuction for Lymphedema
• Administration of Intravenous Diuretics for Acute Exacerbation of Heart Failure
• Dexamethasone Intravitreal Implant for Macular Edema Following Central Retinal Vein Occlusion
• Screening for Impaired Vision in Older Adults
• Interventions for the Improvement of Sleep Quality for Adolescents with Eating Disorders
• Risk Assessment Tools for Venous Thromboembolism in Patients Undergoing Surgery
• Whole Breast Radiotherapy as Part of Breast Conserving Therapy

Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please contact your Canada's Drug Agency Liaison Officer.

Canada's Drug Agency E-Alerts: Subscribe to receive the latest Canada's Drug Agency news, reports, feedback opportunities, and events.